Page last updated: 2024-12-09

methyl indole-3-carboxylate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

methyl indole-3-carboxylate : The methyl ester of indole-3-carboxylic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID589098
CHEMBL ID2270066
CHEBI ID65019
SCHEMBL ID1093530

Synonyms (46)

Synonym
methyl 3-indolecarboxylate
1h-indole-3-carboxylic acid methyl ester
SDCCGMLS-0065824.P001
inchi=1/c10h9no2/c1-13-10(12)8-6-11-9-5-3-2-4-7(8)9/h2-6,11h,1h
methyl indole-3-carboxylate, 99%
I-2505
indole-3-carboxylic acid methyl ester
methyl 1h-indole-3-carboxylate
STK397421
methyl indole-3-carboxylate
942-24-5
HMS1661G01
AKOS000579454
I0491
3-methoxycarbonylindole
3-carbomethoxyindole
FT-0628332
CHEBI:65019 ,
1h-indole-3-carboxylic acid, methyl ester
indole-3-carboxylic acid, methyl ester
3-carbomethoxy indole
3-methoxycarbonyl-1h-indole
methyl indole 3-carboxylate
7T-1502
SCHEMBL1093530
CHEMBL2270066 ,
mfcd00189407
SY020043
methyl 1h-indole-3-carboxylate #
methyl indole-3- carboxylate
F2190-0648
CS-D1229
DTXSID10343334
methylindole-3-carboxylate
Z57164966
bdbm50250885
Q27133581
BCP00917
indole-3-carboxylicacidmethylester
AMY23351
indole-3-carboxylic acid methyl ester, 99%
AB9732
PB47482
3-methoxycarbonylindole, 3-carbomethoxyindole, methyl indolyl-3-carboxylate
EN300-18395
HY-79635
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
indolesAny compound containing an indole skeleton.
methyl esterAny carboxylic ester resulting from the formal condensation of a carboxy group with methanol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bromodomain-containing protein 4Homo sapiens (human)IC50 (µMol)100.00000.00040.40329.0500AID1477686
CREB-binding proteinHomo sapiens (human)IC50 (µMol)99.00001.30006.689210.0000AID1477685
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (56)

Processvia Protein(s)Taxonomy
regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
chromatin organizationBromodomain-containing protein 4Homo sapiens (human)
DNA damage responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription elongation by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of DNA-templated transcriptionBromodomain-containing protein 4Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIBromodomain-containing protein 4Homo sapiens (human)
regulation of inflammatory responseBromodomain-containing protein 4Homo sapiens (human)
positive regulation of T-helper 17 cell lineage commitmentBromodomain-containing protein 4Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
response to hypoxiaNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron migrationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
response to amphetamineNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-templated transcriptionNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
adult locomotory behaviorNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
post-embryonic developmentNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
central nervous system projection neuron axonogenesisNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
habenula developmentNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cellular response to oxidative stressNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of dopamine metabolic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
dopamine biosynthetic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron maturationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of neuron apoptotic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of respiratory gaseous exchangeNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
fat cell differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron apoptotic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
general adaptation syndromeNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
canonical Wnt signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
dopaminergic neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
midbrain dopaminergic neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
central nervous system neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
response to hypoxiaCREB-binding proteinHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
chromatin remodelingCREB-binding proteinHomo sapiens (human)
regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
protein acetylationCREB-binding proteinHomo sapiens (human)
signal transductionCREB-binding proteinHomo sapiens (human)
canonical NF-kappaB signal transductionCREB-binding proteinHomo sapiens (human)
regulation of smoothened signaling pathwayCREB-binding proteinHomo sapiens (human)
negative regulation of transcription by RNA polymerase ICREB-binding proteinHomo sapiens (human)
N-terminal peptidyl-lysine acetylationCREB-binding proteinHomo sapiens (human)
positive regulation of transforming growth factor beta receptor signaling pathwayCREB-binding proteinHomo sapiens (human)
protein destabilizationCREB-binding proteinHomo sapiens (human)
cellular response to nutrient levelsCREB-binding proteinHomo sapiens (human)
cellular response to UVCREB-binding proteinHomo sapiens (human)
homeostatic processCREB-binding proteinHomo sapiens (human)
embryonic digit morphogenesisCREB-binding proteinHomo sapiens (human)
positive regulation of DNA-templated transcriptionCREB-binding proteinHomo sapiens (human)
positive regulation of transcription by RNA polymerase IICREB-binding proteinHomo sapiens (human)
rhythmic processCREB-binding proteinHomo sapiens (human)
protein-containing complex assemblyCREB-binding proteinHomo sapiens (human)
regulation of cellular response to heatCREB-binding proteinHomo sapiens (human)
positive regulation of protein localization to nucleusCREB-binding proteinHomo sapiens (human)
positive regulation of double-strand break repair via homologous recombinationCREB-binding proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (37)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingBromodomain-containing protein 4Homo sapiens (human)
p53 bindingBromodomain-containing protein 4Homo sapiens (human)
chromatin bindingBromodomain-containing protein 4Homo sapiens (human)
transcription coregulator activityBromodomain-containing protein 4Homo sapiens (human)
transcription coactivator activityBromodomain-containing protein 4Homo sapiens (human)
protein bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II CTD heptapeptide repeat kinase activityBromodomain-containing protein 4Homo sapiens (human)
enzyme bindingBromodomain-containing protein 4Homo sapiens (human)
lysine-acetylated histone bindingBromodomain-containing protein 4Homo sapiens (human)
RNA polymerase II C-terminal domain bindingBromodomain-containing protein 4Homo sapiens (human)
P-TEFb complex bindingBromodomain-containing protein 4Homo sapiens (human)
histone reader activityBromodomain-containing protein 4Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
beta-catenin bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear retinoid X receptor bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein heterodimerization activityNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear glucocorticoid receptor bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription coactivator bindingCREB-binding proteinHomo sapiens (human)
p53 bindingCREB-binding proteinHomo sapiens (human)
chromatin bindingCREB-binding proteinHomo sapiens (human)
damaged DNA bindingCREB-binding proteinHomo sapiens (human)
transcription coactivator activityCREB-binding proteinHomo sapiens (human)
transcription corepressor activityCREB-binding proteinHomo sapiens (human)
histone acetyltransferase activityCREB-binding proteinHomo sapiens (human)
protein bindingCREB-binding proteinHomo sapiens (human)
zinc ion bindingCREB-binding proteinHomo sapiens (human)
acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
MRF bindingCREB-binding proteinHomo sapiens (human)
histone H3K18 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
histone H3K27 acetyltransferase activityCREB-binding proteinHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
peptide-lysine-N-acetyltransferase activityCREB-binding proteinHomo sapiens (human)
peptide lactyltransferase activityCREB-binding proteinHomo sapiens (human)
DNA-binding transcription factor bindingCREB-binding proteinHomo sapiens (human)
chromatin DNA bindingCREB-binding proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
condensed nuclear chromosomeBromodomain-containing protein 4Homo sapiens (human)
nucleusBromodomain-containing protein 4Homo sapiens (human)
nucleoplasmBromodomain-containing protein 4Homo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cytoplasmNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear speckNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein-containing complexNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
nucleusCREB-binding proteinHomo sapiens (human)
nucleoplasmCREB-binding proteinHomo sapiens (human)
cytoplasmCREB-binding proteinHomo sapiens (human)
cytosolCREB-binding proteinHomo sapiens (human)
nuclear bodyCREB-binding proteinHomo sapiens (human)
chromatinCREB-binding proteinHomo sapiens (human)
histone acetyltransferase complexCREB-binding proteinHomo sapiens (human)
transcription regulator complexCREB-binding proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (35)

Assay IDTitleYearJournalArticle
AID1477687Selectivity ratio of IC50 for His tagged recombinant BRD4 bromodomain 1 (unknown origin) to IC50 for His tagged recombinant CBP (unknown origin)2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors.
AID1171197Antimicrobial activity against Escherichia coli 1116 after 24 to 48 hrs by serial dilution method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1101160Fungicidal activity against Cryphonectria parasitica assessed as inhibition of fungal growth at 25 ug after 7 days2000Journal of agricultural and food chemistry, Oct, Volume: 48, Issue:10
Isolation and characterization of fungal inhibitors from Epichloë festucae.
AID1885212Inverse agonist activity at Nurr1 (unknown origin) assessed as remaining activity relative to control2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID1477685Inhibition of His tagged recombinant CBP (unknown origin) by TR-FRET assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors.
AID1171196Antimicrobial activity against Paenibacillus polymyxa 36 after 24 to 48 hrs by serial dilution method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1171208Cytotoxicity against human PC3 cells by MTT assay2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1477704Inhibition of His tagged recombinant CBP (unknown origin) at 50 uM by HTS assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors.
AID1372697Inhibition of mushroom tyrosinase using tyrosine as substrate pretreated for 5 mins followed by substrate addition measured after 20 mins by ELISA2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
Characterization of tyrosinase inhibitory constituents from the aerial parts of Humulus japonicus using LC-MS/MS coupled online assay.
AID1171202Antimicrobial activity against Wickerhamomyces anomalus 6766 after 24 to 48 hrs by serial dilution method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1171209Cytotoxicity against human KB3-1 cells by MTT assay2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1171199Antimicrobial activity against Pseudomonas aeruginosa 50071 after 24 to 48 hrs by serial dilution method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1780506Inverse agonist activity at Gal4-fused human Nurr1 LBD expressed in HEK293T cells co-expressing firefly luciferase assessed as luciferase activity by hybrid reporter gene assay2021Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20
Development and Profiling of Inverse Agonist Tools for the Neuroprotective Transcription Factor Nurr1.
AID1171200Antimicrobial activity against Saccharomyces cerevisiae 70449 after 24 to 48 hrs by serial dilution method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1885211Inverse agonist activity at Nurr1 (unknown origin)2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID1171198Antimicrobial activity against Chromobacterium violaceum 30191 after 24 to 48 hrs by serial dilution method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1171211Cytotoxicity against human A549 cells by MTT assay2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1101161Fungicidal activity against Cryphonectria parasitica assessed as inhibition of fungal growth at 50 ug after 7 days2000Journal of agricultural and food chemistry, Oct, Volume: 48, Issue:10
Isolation and characterization of fungal inhibitors from Epichloë festucae.
AID1171194Antimicrobial activity against Staphylococcus aureus 346 after 24 to 48 hrs by serial dilution method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1171212Cytotoxicity against human SKOV3 cells by MTT assay2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1780507Inverse agonist activity at Gal4-fused human Nurr1 LBD expressed in HEK293T cells co-expressing firefly luciferase assessed as remaining activity by hybrid reporter gene assay relative to control2021Journal of medicinal chemistry, 10-28, Volume: 64, Issue:20
Development and Profiling of Inverse Agonist Tools for the Neuroprotective Transcription Factor Nurr1.
AID1171205Cytotoxicity against mouse L929 cells by MTT assay2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1101159Fungicidal activity against Cryphonectria parasitica assessed as inhibition of fungal growth at 12.5 ug after 7 days2000Journal of agricultural and food chemistry, Oct, Volume: 48, Issue:10
Isolation and characterization of fungal inhibitors from Epichloë festucae.
AID1171201Antimicrobial activity against Candida albicans 1665 after 24 to 48 hrs by serial dilution method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1171195Antimicrobial activity against Mycobacterium diernhoferi 43542 after 24 to 48 hrs by serial dilution method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1171204Antimicrobial activity against Mucor hiemalis 2656 after 24 to 48 hrs by serial dilution method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1171210Cytotoxicity against human MCF7 cells by MTT assay2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1101162Fungicidal activity against Cryphonectria parasitica assessed as inhibition of fungal growth at 100 ug after 7 days2000Journal of agricultural and food chemistry, Oct, Volume: 48, Issue:10
Isolation and characterization of fungal inhibitors from Epichloë festucae.
AID1171193Antimicrobial activity against Nocardia sp. 43069 after 24 to 48 hrs by serial dilution method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1477686Inhibition of His tagged recombinant BRD4 bromodomain 1 (unknown origin) by TR-FRET assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors.
AID1171203Antimicrobial activity against Trichosporon oleaginosus 11815 after 24 to 48 hrs by serial dilution method2014Journal of natural products, Nov-26, Volume: 77, Issue:11
Nannozinones and sorazinones, unprecedented pyrazinones from myxobacteria.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's6 (60.00)24.3611
2020's3 (30.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.24

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.24 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index5.27 (4.65)
Search Engine Demand Index43.31 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.24)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (10.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (90.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]